EyePoint, Inc. (EYPT) stock intrinsic value fair value estimate & owner earnings analysis

EyePoint, based in Watertown, Massachusetts, is now essentially a one-product development company. Its future rests on DURAVYU, a small insert injected into the eye that releases vorolanib, a drug licensed from Equinox Science, for about six months. DURAVYU is in two Phase 3 trials for wet age-related macular degeneration, LUGANO (432 patients) and LUCIA (475 patients), which finished enrolling in May and July 2025 and compare it with aflibercept (sold as EYLEA). Two Phase 3 trials in diabetic macular edema, COMO and CAPRI, began dosing in February 2026. EyePoint stopped selling DEXYCU in 2023 and licensed YUTIQ in the U.S. to Alimera (now ANI) for $75 million upfront plus $7.5 million paid in 2024. Revenue has almost disappeared: $31.4 million in 2025, most of it money received in earlier years being recognised on paper, and $1.2 million in the first half of 2026. What the business earns. We measure the cash a business produces for its owners after its real costs, including stock-based pay and the spending needed to keep operating. On that measure EyePoint has lost money in every one of the last ten years. It became a pure development company after the 2023 YUTIQ licence, and since then it has lost $2.47 a share in 2024, $3.24 a share ($237 million) in 2025 and roughly $180 million in the first half of 2026 alone. Operating cash flow was slightly positive in 2023 only because of the YUTIQ upfront, which we treated as a one-off receipt. The company has no meaningful debt. It held $180.5 million in cash and investments at June 30, 2026, about $2.09 a share. In March 2026 it said its cash would last into the fourth quarter of 2027, which implies much lower spending than the first-half 2026 rate once the wet AMD trials end. Because the business uses cash rather than producing it, we value each case as the cash on hand, minus what that case would burn, plus whatever DURAVYU eventually earns back, all discounted at 6%. This assumes new money is raised at fair prices; raising it cheaply would lower every case. Bear case: $0.32 a share. The wet AMD trials fail to show DURAVYU is as good as aflibercept, or approval is refused. One named risk is that about 75% of the Phase 3 patients had never been treated, while the Phase 2 trial enrolled only previously treated patients. In this case EyePoint closes out its trials, stops the diabetic macular edema program and winds down. That costs about $130 million in the rest of 2026 and $25 million in 2027, including the roughly $4.7 million agreed in principle in early 2026 to settle a Justice Department investigation into how DEXYCU was marketed. Little is left for shareholders, but the value stays positive because the company does not owe more than it holds. Base case: $2.02. Both wet AMD trials succeed. We treat that as the median outcome for three reasons. The Phase 2 DAVIO 2 trial against the same comparator came within 0.3 to 0.4 letters of aflibercept on the eye chart, where the allowed margin was 4.5. An independent safety committee let both Phase 3 trials continue unchanged in November 2025. And a commercial plant in Northbridge, Massachusetts is already being scaled up. DURAVYU is approved in 2028. Sales reach about $560 million a year by 2035, roughly 13% of the $4.38 billion Regeneron reported for U.S. EYLEA and EYLEA HD sales in 2025. After manufacturing, the high-single to low-double digit royalty owed to Equinox, and about $240 million a year of selling and research costs, peak earnings are about $200 million a year. Getting there takes about $1.2 billion of further losses, so around $1 billion must be raised beyond today's cash. Sales ease after the vorolanib compound patent expires in September 2037, hold until the U.S. DURAVYU patent expires in 2043, and fall to zero by 2046, because nothing we can identify replaces them. We kept this case modest on purpose. EyePoint's best year selling YUTIQ and DEXYCU brought $35.3 million of product sales, in 2021, and it later exited both. U.S. EYLEA sales also fell by more than a quarter in 2025, which shows how fast money in this category moves. Bull case: $26.89. Both diseases succeed and six-month dosing is widely adopted. Sales reach about $1.1 billion by 2035, about a quarter of 2025 U.S. EYLEA sales, and peak earnings reach about $485 million. The business breaks even by 2030 after roughly $910 million of further losses. What the shares appear to be worth. Almost all of the gap between $0.32 and $26.89 depends on the Phase 3 results. Wet AMD data were expected from mid-2026. The filings we could review do not include them, and once published they will largely decide where in this range the value lies. Other named risks: a July 2024 FDA warning letter about YUTIQ manufacturing at Watertown, which the company says it has fully addressed; a single supplier of vorolanib; a corporate integrity agreement that comes with the government settlement; and competition from Vabysmo, EYLEA HD and other long-acting treatments in development. No margin-of-safety price applies on price alone. The base case already assumes the trials succeed, so success would not raise our $2.02 estimate. It would only remove the failure outcome. If both wet AMD trials meet their goal and the company can pay its way to an FDA decision without more than doubling its share count, the margin-of-safety price is $1.10. That is about 45% below $2.02, to cover the risks that would remain: a weak commercial track record, roughly $1 billion still to raise, and fast-moving competition.